miR-125a Induces HER2 Expression and Sensitivity to Trastuzumab in Triple-Negative Breast Cancer Lines.
ErbB2
TNBC
apoptosis
epigenetics
miRNA
migration
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
21
09
2019
accepted:
04
02
2020
entrez:
19
3
2020
pubmed:
19
3
2020
medline:
19
3
2020
Statut:
epublish
Résumé
The EGFR/HER2 signaling network is an effective therapeutic target for HER2-positive cancers, which are known for their aggressive biological course. Evidence indicates that the EGFR/HER2 network plays a role in the aggressive basal-like subtype as well. Here, we studied the potential role of miR-125a-3p as a modulator of the EGFR/HER2 pathway in basal-like breast cancer. Over-expression of miR-125a-3p reduced the migratory capability of MDA-MB-231 cells and led to an increase in the expression of ErbB2 transcript and protein. The induced ErbB2 responded to trastuzumab and underwent internalization and subsequent intra-lysosomal degradation. Trastuzumab treatment further reduced the migratory capability and induced the apoptosis of the cells. An
Identifiants
pubmed: 32185126
doi: 10.3389/fonc.2020.00191
pmc: PMC7058585
doi:
Types de publication
Journal Article
Langues
eng
Pagination
191Informations de copyright
Copyright © 2020 Ninio-Many, Hikri, Burg-Golani, Stemmer, Shalgi and Ben-Aharon.
Références
Nat Rev Drug Discov. 2010 Oct;9(10):775-89
pubmed: 20885409
J Biol Chem. 2007 Jan 12;282(2):1479-86
pubmed: 17110380
BMC Cancer. 2010 Jun 22;10:318
pubmed: 20569443
Int J Oncol. 2013 May;42(5):1734-42
pubmed: 23525486
Breast Cancer Res Treat. 2012 Jul;134(1):21-30
pubmed: 22234518
Nucleic Acids Res. 2013 Nov;41(21):9688-704
pubmed: 23990326
Crit Rev Biochem Mol Biol. 2013 Jan-Feb;48(1):51-68
pubmed: 23163351
Clin Cancer Res. 2011 May 1;17(9):2725-33
pubmed: 21220473
Clin Breast Cancer. 2009 Jun;9 Suppl 2:S73-81
pubmed: 19596646
J Cell Biol. 2005 Nov 7;171(3):505-16
pubmed: 16275754
Cancer Invest. 2013 Oct;31(8):538-44
pubmed: 24044511
Cancer Treat Rev. 2012 Oct;38(6):698-707
pubmed: 22178455
Expert Opin Investig Drugs. 2019 Nov;28(11):977-988
pubmed: 31594388
J Natl Cancer Inst. 2013 Mar 20;105(6):393-404
pubmed: 23355761
Front Pharmacol. 2015 Nov 24;6:283
pubmed: 26635612
Nat Struct Mol Biol. 2008 Apr;15(4):334-6
pubmed: 18388906
Signal Transduct Target Ther. 2017;2:
pubmed: 28435746
Int J Oncol. 2012 May;40(5):1477-82
pubmed: 22322911
Nat Cell Biol. 2000 May;2(5):249-56
pubmed: 10806474
Semin Cancer Biol. 2019 Dec;59:80-91
pubmed: 31173856
Oncoscience. 2014 Apr 30;1(4):250-261
pubmed: 25594017
J Cell Sci. 2013 Jul 1;126(Pt 13):2867-76
pubmed: 23606749